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A B S T R A C T   
Gene transfer to mesenchymal stem cells (MSCs) has arisen as a powerful approach to increase the therapeutic 
potential of this effective cell population. Over recent years, niosomes have emerged as self-assembled carriers 
with promising performance for gene delivery. The aim of our work was to develop effective niosomes-based 
DNA delivery platforms for targeting MSCs. Niosomes based on 1,2-di-O-octadecenyl-3-trimethylammonium 
propane (DOTMA; 0, 7 or 15%) as cationic lipid, cholesterol as helper lipid, and polysorbate 60 as non-ionic 
surfactant, were prepared using a reverse phase evaporation technique. Niosomes dispersions (filtered or not) 
and their corresponding nioplexes with a lacZ plasmid were characterized in terms of size, charge, protection, 
and complexation abilities. DOTMA concentration had a large influence on the physicochemical properties of 
resulting nioplexes. Transfection efficiency and cytotoxic profiles were assessed in two immortalized cell lines of 
MSCs. Niosomes formulated with 15% DOTMA provided the highest values of β-galactosidase activity, being 
similar to those achieved with Lipofectamine®, but showed less cytotoxicity. Filtration of niosomes dispersions 
before adding to the cells resulted in a loss of their biological activities. Storage of niosomes formulations (for 30 
days at room temperature) caused minor modification of their physicochemical properties but also attenuated 
the transfection capability of the nioplexes. Differently, addition of the lysosomotropic agent sucrose into the 
culture medium during transfection or to the formulation itself improved the transfection performance of non- 
filtered niosomes. Indeed, steam heat-sterilized niosomes prepared in sucrose medium demonstrated trans-
fection capability.   
1. Introduction 
Mesenchymal stem cells (MSCs) constitute a pivotal cell population 
for cell therapy in regenerative medicine. Key attributes of MSCs as their 
capacity to differentiate into various lineages, feasibility of isolation and 
expansion in vitro, homing and immunomodulatory properties, make 
them an appealing cell source for tissue repair [1,2]. These properties 
also point out MSCs as an excellent target for gene therapy approaches as 
a way to reinforce their therapeutic potential for tissue repair [3]. Ge-
netic modification of MSCs has emerged as a promising tool for the 
treatment of different tissue pathologies as those affecting musculo-
skeletal [4–7], cardio-vascular [8–10] or retinal tissues [8]. 
Among the different types of gene vectors tested to genetically 
modify MSCs, nonviral carriers represent the safest tools, overcoming 
immunogenicity and tumorigenic risks associated with viral vectors [9]. 
Moreover, nonviral systems can transfer longer genes and be produced 
in larger amounts at lower cost [10]. Current nonviral gene therapy 
approaches focus on the complexation of negatively charged DNA 
molecules with cationic polymers (e.g., poly-L-lysine, poly-
ethyleneimine, poly(amidoamine), chitosan) [11] or lipids (e.g., lipo-
somes) [12–14] in order to facilitate their entry in the cell. 
Notwithstanding, gene transfer efficacy via nonviral vectors is still lower 
when compared with that of their viral counterparts [9,10]. Therefore, 
improved nonviral vectors are being actively researched. 
Niosomes are self-assembled vesicular nanocarriers composed of 
non-ionic surfactants, helper lipids and charge modifiers [15] that have 
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recently emerged as promising nonviral gene delivery systems [16–18]. 
Replacement of phospholipids by non-ionic surfactants notably im-
proves the stability of niosomes compared to liposomes while still pre-
serving adequate cytocompatibility [19]. Niosomes have been 
formulated by combination of commercial cationic lipids [20–24] or 
chemically modified ones [18,20,21,25] with non-ionic surfactants 
including polysorbate 20 [23], polysorbate 60 [20–22,24] or poly-
sorbate 80, either solely [18,20,21,23,25] or blended with poloxamer 
[20,21]. Helper lipids as squalene [20,21,23,25], cholesterol [25] or 
lycopene [20–22] have been shown to improve niosomes physical 
properties. Most of these niosomes formulations have been tested to 
target retina [23–25] or central nervous system [20,22] cells. None-
theless, only a few recent studies have revealed the feasibility of nio-
somes to genetically modify MSCs, which were from mouse origin 
[18,21]. 
The aim of this work was to elucidate whether niosomes could be 
effective DNA delivery platforms for targeting immortalized human 
MSCs cell lines (iMSCs) obtained from aged donors [26]. Selected iMSCs 
cell lines have previously shown to avoid senescence and proliferation 
problems associated to primary cultures while maintaining their mul-
tipotency, therefore being potential tools for regenerative medicine 
research [26,27]. The hypothesis of this study is that a good balance 
between DNA condensation capability, gene transfection efficiency and 
cytocompatibility can be achieved by tuning the content in cationic lipid 
1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA). Thus, 
to carry out the work, niosomes based on polysorbate 60 as non-ionic 
surfactant and cholesterol as helper lipid were prepared covering a 
wide range in DOTMA content (0, 7 and 15%) using a reverse phase 
evaporation technique [15]. Since nanocarrier purification is a required 
step for pre-clinical translation of developed formulations the effects of 
filtration and heat sterilization under isotonic conditions on the ability 
of the niosomes to genetically modify the iMSCs were investigated. Both 
filtration and autoclaving have been mentioned in previous reports to 
compromise vesicles stability and further performance as non-viral 
vectors [28]. Niosomes and corresponding nioplexes with a lacZ 
encoding plasmid were characterized in terms of size, polydispersity 
index (PDI), zeta potential, protection and complexation abilities, and 
transfection efficiency of iMSCs cultures. The addition of the lysoso-
motropic agent sucrose firstly to the cells medium and lastly to the 
formulation itself were explored as a way to enhance the performance of 
the developed gene delivery systems. Finally, the physicochemical sta-
bility of the niosomes and the biological properties of the nioplexes upon 
long-term storage were monitored. 
2. Materials and methods 
2.1. Materials 
Polysorbate 60 (P60, Tween 60, MW 1311.7 g/mol, HLB 14.9), 
paraformaldehyde (37% v/v), Dulbecco's Modified Eagle's Medium 
(DMEM) and cholesterol (MW 386.65 g/mol) were purchased from 
Sigma Aldrich (St Louis, MO, USA). 1,2-Di-O-octadecenyl-3-trimethy-
lammonium propane (chloride salt) (DOTMA, MW 670.575 g/mol) 
was obtained from Avanti Polar Lipids (Alabaster, AL, USA). Fetal 
bovine serum (FBS), penicillin/streptomycin (P/S), Tris-borate-EDTA 
(TBE), Lipofectamine® Stem (LPF), Opti-MEM™ reduced serum me-
dium, SYBR Green Gold (10,000 X), DNase I (1000 U), sodium dodecyl 
sulfate (SDS, MW 288.38 g/mol), dichloromethane, agarose, 4′,6-dia-
midino-2-phenylindole dihydrochloride (DAPI), Triton X-100 (MW 
646.86 g/mol) and pCMV-SPORT-βgal (placZ, bp 7853), were from 
Gibco-ThermoFisher Scientific (Madrid, Spain). WST-1 was purchased 
from Roche (Mannheim, Germany). β-glo was from Promega (Madison, 
WI, USA). Label IT® Nucleic Acid Labeling kit Cy3 was from Mirus Bio 
(Madison, WI, USA). The 18-well μ-chamber slides were from Ibidi 
(Gräfelfing, Germany). 
2.2. Niosome preparation 
P60 (35.3 mg), cholesterol (4.4 mg) (P60: cholesterol 1:0.42 mol 
ratio) and DOTMA (0, 1.8 or 3.8 mg to have 0, 7 and 15 mol%) were 
dissolved together in dichloromethane (2 mL). The solvent was then 
evaporated in a rotary evaporator under 400 mbar pressure at 40 ◦C to 
form a thin film on the bottom of the flask. The film was desiccated for 
30 min under vacuum to remove traces of solvent, hydrated with 5 mL 
Opti-MEM and sonified for 90 s at 20% amplitude with a probe (1/8′′
diameter tapered horn) fitted to a Branson Digital Sonifier 450 (Marshall 
Scientific, Hampton, NH, USA). Half of the niosomes dispersion was 
filtered using 0.45 μm polyethersulfone (PES) membranes (Filter-Lab, 
Filtros Anoia, Barcelona, Spain) and designed as filtered dispersions, F. 
The other half niosome dispersion was directly used without filtration 
and designed as non-filtered dispersion, wF. 
An additional batch of niosomes was prepared as above but the film 
was hydrated with 300 mM sucrose aq. solution, subsequent sterilized 
by steam heat (sh) and used without filtration. This batch was designed 
as sh. 
2.3. Plasmid propagation and formation of nioplexes 
The pCMV-SPORT-βgal reporter plasmid (placZ) was propagated, 
purified, and quantified following the instructions from manufacturer. 
Labelling of placZ with Cy3 was performed using a Label IT Nucleic Acid 
Labeling kit following the guidelines from the supplier. 
Nioplexes were formed by mixing an appropriate volume (always 
100 ng of plasmid) of a stock solution of a placZ (1 mg/mL) with 
different volumes of niosomes (with 7 and 15% DOTMA) in Opti-MEM 
medium to get cationic lipid/DNA mass ratios (w/w) of 2.5/1, 5/1, 
10/1, 15/1 and 20/1, which were equivalent to cationic amino groups 
(N) to nucleic acid anionic phosphate groups (P) ratio of 1, 2, 5, 7 and 
10, respectively. Nioplexes formulated with 0% DOTMA were prepared 
by mixing the same amount of placZ with the appropriate volumes of 0% 
DOTMA niosomes to get P60/DNA mass ratios (w/w) of 2.5/1, 5/1, 10/ 
1, 15/1 and 20/1. The mixtures were allowed to stand for 30 min at 
room temperature to promote the electrostatic interactions between the 
niosomes and the negatively charged plasmid [24]. 
2.4. Size and zeta potential 
Niosomes and nioplexes (cationic lipid/DNA mass ratios of 2.5/1, 5/ 
1, 10/1, 15/1 and 20/1) were prepared following the same procedures 
described in Sections 2.2 and 2.3. The hydrodynamic diameter, poly-
dispersity index (PDI) (n = 3) and zeta potential (n = 2) of both niosomes 
and nioplexes were measured in water and in Opti-MEM medium at 20 ̊C 
by Dynamic Light Scattering (DLS) and Electrophoretic Light Scattering 
(ELS) using a NanoBrook 90Plus Zeta (Brookhaven Instruments Corpo-
ration, Holtsville, NY, USA). Folded capillary cuvettes (DTS1070) were 
used for the measurements. 
2.5. Agarose gel electrophoresis 
The capacity of niosomes to condense DNA was evaluated by agarose 
gel electrophoresis assay, at the same cationic lipid/DNA (7% and 15% 
DOTMA) or P60/DNA (0% DOTMA) mass ratio described in Section 2.3. 
Naked placZ (control) or niosome-complexed placZ samples (always 
100 ng of plasmid) were run on a 0.8% w/v agarose gel after adding 
DNase I at a final concentration of 1 U DNase per 2.5 μg DNA [18]. The 
mixtures were incubated at 37 ◦C for 30 min. Finally, 7% SDS solution 
was added to release DNA from the nioplexes. The agarose gel was 
immersed in TBE buffer and exposed for 30 min to 100 V. DNA bands 
were stained with SYBR Green, and images were observed under a 
digital Chemi-Doc™ MP Imaging System (Bio-Rad, Madrid, Spain). 
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2.6. Evaluation of niosomes complexation ability 
The ability of niosomes to bind and complex DNA was evaluated by 
means of a fluorescence-exclusion titration assay [29,30]. Briefly, nio-
plexes (0, 7 and 15% DOTMA) were invariably prepared by mixing 0.5 
μg of pDNA with the corresponding amount of niosome dispersions as 
described in Section 2.3. Afterwards, nioplexes were incubated for 30 
min at RT, then SYBR Green (200×; 3 μL) was added, and the mixture 
was incubated for 10 min protected from light. Finally, 10 mM HEPES 
was added to obtain a total volume of 300 μL. Fluorescence measure-
ments were performed with a Synergy HTX Plate Reader (Biotek, 
Winooski, VT, USA) in 96 black well-plates (λexc = 485 nm, λem. = 528 
nm). The complexation efficiency (%) was expressed as relative fluo-
rescence, normalized to the fluorescence of uncomplexed (naked) pDNA 
according to the following equation [10]. 
Complexation efficiency (%) =
Fsample − Fblank
Fnaked pDNA − Fblank
× 100 
In this equation, F is the recorded fluorescence and Fblank represents 
the fluorescence values recorded from the blank, performed by using 
same dilution of SYBR Green (200×) in 10 mM HEPES, but in absence of 
plasmid or niosomes. Each condition was assessed in triplicate. 
2.7. Transmission electron microscopy (TEM) 
Drops (5 μL) of niosome dispersions were placed on carbon coated 
grids. The excess was carefully removed with a filter paper. Samples 
were dyed with uranyl acetate (2% in water), dried, and observed using 
a high resolution JEM-1011 TEM (JEOL USA Inc., Peabody, MA, USA). 
2.8. In vitro cell studies 
Immortalized mesenchymal stem cells (iMSCs; iMSCs#6 and 
iMSCs#13) were kindly donated by Prof. S.M. Diaz-Prado [26]. Cells 
were grown in DMEM supplemented with 10% FBS and 1% P/S and kept 
at 37 ◦C in a humidified atmosphere containing 5% CO2. 
iMSCs cells were seeded in 96 well-plates at an initial density of 104 
cells/well and allowed to attach for 24 h at 37 ◦C before the experiments. 
Cells were exposed to different nioplexes formed upon complexation of 
niosome formulations (0, 7 and 15% DOTMA; wF and F) with placZ 
(always 100 ng of plasmid; cationic lipid or P60/DNA 5/1, 10/1, 15/1 
and 20/1 w/ w mass ratios) in Opti-MEM medium following the pro-
cedure described in Section 2.3. Cells cultured in Opti-MEM without 
nioplexes and cells transfected with the commercial reagent LPF (1 μL/ 
well) were used as negative and positive controls, respectively. Cells 
were incubated with nioplexes or LPF lipoplexes for 3 h at 37 ◦C and 5% 
CO2. After this time, the medium was removed and refreshed with 
growth medium, and cells were allowed to grow for 48 h at 37 ◦C, until 
analysis. 
In parallel, some of the formulations (7 and 15% DOTMA both wF) 
were complexed with placZ (100 ng plasmid; cationic lipid/DNA 5/1 
and 10/1 mass ratio, equivalent to 2 and 5 N/P ratios) and tested under 
the same conditions (cell density and growth time). After adding the 
nioplexes solutions (10 μL), Opti-MEM or Opti-MEM with sucrose (40 
mM) were added to complete a final volume of 100 μL per well. All 
conditions were assessed in triplicate in each cell line (iMSCs#6 and 
iMSCs#13) in two independent experiments. Additionally, a batch of 
niosomes dispersions prepared in 300 mM sucrose and heat sterilized 
(sh) was evaluated under same conditions as described above (100 ng 
plasmid; cationic lipid/DNA 5/1, 10/1 and 15/1 mass ratio, equivalent 
to 2, 5 and 7 N/P ratios). 
2.9. Cell viability assay 
Viability of iMSCs monolayers at 48 h post-transfection with the 
different nioplexes (same formulations and w/w ratios described in 
Section 2.3) was monitored using the tetrazolium salt (WST-1) method 
[31]. Absorbance (A) at 450 nm was measured using a Synergy HTX 
Plate Reader (Biotek, Winooski, VT, USA) and the percent of cell 





Cell numbers upon contact with nioplexes or lipoplexes were esti-
mated from a calibration curve constructed using cultures with known 
number of cells from each cell line (iMSCs#6 and iMSCs#13). 
2.10. Transfection efficiency 
The transfection efficiency achieved with the different nioplexes 
(same formulations and w/w ratios described in Section 2.3) was eval-
uated by using the β-glo reagent [32]. Luminescence measurements 
were performed in white 96 well-plates using a plate reader and 
β-galactosidase activity was expressed as Relative Luminescence Units 
(RLU). Endogenous β-galactosidase activity recorded for the negative 
control was used as blank and subtracted for each condition and group of 
study. 
β − galactosidase activity = RLUsample − RLUnegative control  
2.11. Cellular and nuclear uptake of placZ 
iMSCs (104 cells/well) were seeded in sterile 18-well μ-chamber 
slides and transfected with nioplexes formed with Cy3-labeled placZ 
(100 ng pDNA; cationic lipid/DNA 5/1 and 10/1 w/w mass ratios, 
equivalent to 2 and 5 N/P ratios) at the same conditions described in 
Section 2.7. After 4 h of incubation at 37 ◦C, cells were fixed with 4% 
paraformaldehyde for 10 min at room temperature, and the membrane 
was permeabilized by adding Triton X-100 (0.2% in PBS) for 8 min at 
RT. Then, DAPI (300 nM in PBS) was added to the monolayers in 
darkness as a nuclear counterstain, and incubated for 5 min at room 
temperature [33]. Finally, cells were washed 2 times with PBS and 
observed under a fluorescence inverted microscope Olympus CKX53 
(Olympus, Barcelona, Spain) with rhodamine (Cy3) and UV (DAPI) fil-
ters sets. 
2.12. Stability assays 
Niosomes and nioplexes characterization and in vitro transfection 
studies were repeated after storing the niosomes dispersions for 30 days 
at room temperature protected from light. The nioplexes were prepared 
immediately before testing using the stored niosomes containing 7 or 
15% DOTMA both wF, for cationic lipid/DOTMA 5/1 and 10/1 w/w 
mass ratios, equivalent to 2 and 5 N/P ratios (as described in Section 
2.8). 
2.13. Statistical analysis 
Data were expressed as mean ± standard deviation (SD). Statistical 
analysis was performed using IBM SPSS Statistics version 23 by para-
metric tests (one-way ANOVA; Student's t-test) and non-parametric ones 
(Kruskal-Wallis, Multiple Range, U-Mann Whitney), when appropriate 
in each case. A p ≤ 0.05 was considered statistically significant. 
3. Results 
3.1. Preparation and physicochemical characterization of niosomes and 
nioplexes 
Niosomes were prepared using a quite hydrophilic surfactant (P60) 
as main component, cholesterol as helper lipid, and DOTMA as lipid that 
may confer cationic charges. Cholesterol was included at the minimum 
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proportion required to form niosomes in the 100 nm range, according to 
preliminary experiments. DOTMA was included at three levels: 0, 7 and 
15 mol% in order to elucidate the effect of the cationic charges on the 
transfection efficiency. Niosomes were prepared using the reverse phase 
evaporation method and characterized in terms of particle size, zeta 
potential and polydispersity index (PDI). Table 1 summarizes main 
physicochemical features from freshly prepared niosomes before (wF) 
and after (F) filtration. 
Freshly prepared niosomes (non-filtered, wF) showed a decrease in 
size as the content in DOTMA increased. Relevantly, the mean size of the 
niosomes prepared with 0% and 7% DOTMA decreased in the first few 
days after preparation (Fig. 1). Statistical analysis revealed that nio-
somes without DOTMA at time 0, 24, 96 and 120 h were significantly 
larger (ANOVA, p < 0.001; multiple range test) than niosomes stored 
beyond that time. The mean size of niosomes with 7% DOTMA was also 
greater in the first few days, but the data dispersion was very broad and 
no statistical differences could be seen. Nevertheless, homogeneity in 
size was clearly observed as a function of time, with values converging 
toward 100 nm. The polydispersity index (PDI) (Fig. S1 in Supporting 
Information) showed highly variable values in the first few days after 
preparation and then levelled in 0.5–0.6 range. Differently, the zeta 
potential was stable over the whole 30-day period. Niosomes prepared 
with 15% DOTMA (non-filtered) as well as any filtered formulation 
exhibited more homogeneous and stable values of size, PDI and Z-po-
tential (no statistically significant differences in the 30 days of storage). 
This finding suggests that both an increase in DOTMA proportion and 
filtration facilitate the attaining of self-assembly equilibrium during 
niosome formation. A representative TEM image of non-filtered 15% 
DOTMA niosomes is shown in Fig. S2 (Supporting Information). 
Nioplexes formed upon complexation of placZ with niosomes pre-
pared with 0% (Fig. 2A), 7% (Fig. 2B) and 15% (Fig. 2C) DOTMA sub-
jected (F) or not (wF) to filtration were characterized regarding size and 
zeta potential (Fig. 2 upper panels) and agarose gel electrophoresis as-
says in presence of DNase (Fig. 2 lower panels). Nioplexes formulated 
with 0% DOTMA exhibited the biggest sizes, being around 360 nm in the 
filtered dispersions, and larger than 600 nm in the non-filtered ones (p <
0.001) (Fig. 2A). Nioplexes prepared with 7 and 15% DOTMA disper-
sions had sizes around 180 nm before filtration (wF) and 140 nm after 
filtration (F) (p < 0.05) (Fig. 2B and C). These differences were more 
evident at lower DOTMA/DNA mass ratios; nioplexes formed from F 
dispersions had smaller sizes (p < 0.05 at DOTMA/DNA ratios of 2.5/1 
and 10/1). In general, PDI was also lower in all filtered niosomes for-
mulations (0, 7 and 15% DOTMA); nevertheless, no statistical significant 
differences in this parameter were observed when compared with wF 
dispersions. Irrespective of the DOTMA/DNA w/w ratio considered, the 
size of nioplexes was similar for the two filtered 7% and 15% DOTMA 
formulations tested. Similar trend was observed in nioplexes formed 
using same formulations (7% and 15%) from wF dispersions. 
Conversely, niosomes formulated without DOTMA had the highest sizes 
of nioplexes in both wF and F dispersions (p < 0.001) when compared 
with 7 or 15% DOTMA formulations (Fig. 2A–C). Focusing on DOTMA/ 
DNA mass ratios, all formulations regardless whether they were filtered 
or not, showed a decrease in nioplexes sizes between the lowest (2.5/1) 
and the highest (20/1) ratio tested (p < 0.05). 
The zeta potential of nioplexes showed also a DOTMA-concentration 
dependence effect. All nioplexes prepared with 0% DOTMA exhibited a 
negative zeta potential, which was significantly lower to that achieved 
with 7 or 15% DOTMA formulations from wF niosomes (p < 0.05). 
Nioplexes formulated with 7% DOTMA showed an increase in electro- 
positivity with the raise of DOTMA/DNA ratio, from − 10.0 ± 1.1 mV 
up to +25.9 ± 2.1 mV for the wF dispersions (p < 0.01), and from − 6.3 
± 0.0 mV up to +9.4 ± 4.4 mV for the filtered ones. The same trend was 
observed for 15% DOTMA nioplexes, reaching potential values up to 
+28.8 ± 0.9 mV in wF dispersions and up to +35.6 ± 0.1 mV in F ones (p 
< 0.01) at 20/1 DOTMA/DNA ratio. No differences in size and zeta 
potential values were observed when nioplexes formed from 7% or 15% 
DOTMA niosomes were prepared in Opti-MEM medium (data not 
shown). 
Agarose gel electrophoresis assays in presence of DNase I are sum-
marized in Fig. 2A–C; lower panels. 0% DOTMA niosomes failed to 
condense and therefore to protect the DNA against enzymatic digestion, 
as confirmed by the absence of bands, except for nioplexes formed at the 
highest P60/DNA w/w ratio (20/1) (Fig. 2A). Conversely, an enhanced 
capacity of protection was noticed by increasing DOTMA/DNA ratio in 
7% DOTMA and 15% DOTMA formulations (Fig. 2B and C). After the 
addition of SDS, both 7% DOTMA and 15% DOTMA nioplexes formu-
lations showed SC (supercoiled) and OC (open circular) bands corre-
sponding to the released DNA. Moreover, non-filtered formulations 
demonstrated enhanced protection of complexed DNA from lower 
DOTMA/DNA ratios in 7% DOTMA formulations (Fig. 2B). 
3.2. Complexation of DNA with the niosome formulations 
The ability of the different niosome formulations to efficiently 
condense placZ was then evaluated applying the SYBR green dye 
exclusion assay (Fig. 3). Filtered 7% DOTMA (black line) and 15% 
DOTMA (red line) niosome formulations showed lower fluorescence 
values compared with 0% DOTMA niosomes (blue line) (p < 0.05). The 
data confirmed that 0% DOTMA niosomes were not able to make a 
complex with DNA, except when there was a large excess of P60 to DNA. 
A reduction in fluorescence values was also observed in wF dispersions 
of 7% DOTMA (black dot line) and 15% DOTMA (red dot line) niosomes 
when compared to those prepared without DOTMA (blue dot line) (p <
0.01). 
Specifically, nioplexes prepared with 7% DOTMA and 15% DOTMA 
showed a reduction in relative fluorescence units with the increase in 
DOTMA/DNA ratios. An increment in complexation ability from 
Table 1 
Physical features of non-filtered (wF) and filtered (F) niosomes after 24 h 
preparation. Mean values ± standard deviation (n = 3).  
Parameters Without filtration (wF) Filtered (F) 
DOTMA 
(mol%) 
0 7 15 0 7 15 

































± 5.2  
Time (days)
































Fig. 1. Evolution of the size of niosomes during storage at room temperature 
protected from light. * depicts p < 0.001 for particle size differences between 
0% DOTMA niosomes before and after filtration. 
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cationic lipid/DNA ratio 2.5/1 was evidenced in all filtered niosomes 
formulations (p < 0.01). Nioplexes formulated with non-filtered nio-
somes showed a more gradual decrease of fluorescence values (p < 0.05 
when compared with 5/1 and 20/1 cationic lipid/DNA ratios. Interest-
ingly, filtered 7% DOTMA and 15% DOTMA formulations exhibited 
higher ability for making complexes with the plasmid (60–80% 
complexation) than the non-filtered ones (40–50% complexation) (p <
0.001). 
3.3. In vitro transfection of iMSCs 
Based on the data referred above, in vitro transfection assays of iMSCs 
were carried out using dispersions (F and wF) of both 7% and 15% 
DOTMA niosomes, at cationic lipid/DNA 5/1, 10/1, 15/1 and 20/1 w/w 
ratios. Assays were performed in two different cell lines from iMSCs 
(iMSCs#6 and iMSCs#13) [38]. 
The β-galactosidase activity and cell viability of iMSCs are summa-
rized in Fig. 4. A preliminary screening on transfection efficiency 
(Fig. 4A) in iMSCs#6 (upper panel) and iMSCs#13 (lower panel) cell 
lines, showed significantly higher values of transfection when non- 
filtered dispersions were used compared with filtered formulations (p 
< 0.01). These latter formulations exhibited RLU values close to those 
recorded for the negative control. Focusing on wF niosome dispersions, 
no differences in RLU values were observed between 7% DOTMA and 
15% DOTMA formulations, in none of the two cell lines studied. When 
comparing the transfection efficiency of wF niosomes to that achieved 
with the commercial golden standard Lipofectamine (LPF; positive 
control), no differences were noticed in the iMSCs#13 cell line (Fig. 4B 
lower panel). 15% DOTMA niosomes also attained comparable values in 
the iMSCs#6 cell line (Fig. 4B upper panel). Interestingly, the number of 
β-galactosidase expressing cells was always higher upon transfection 
with 7% DOTMA or 15% DOTMA niosomes formulations when 
compared with those exposed to Lipofectamine (p < 0.001) (Fig. 4B blue 
and green lines). 
Regarding DOTMA/DNA mass ratios, while 7% DOTMA nioplexes 
were more efficient when used at the lowest ratio tested (5/1), the 15% 
DOTMA ones achieved the highest efficiency mean value at an inter-
mediate ratio (10/1), although no statistical differences were observed 
when compared to other mass ratios studied, in none of the two iMSCs 
cell lines studied (Fig. 4B). 
High percentages of cell survival were noted in both iMSCs#6 
(~66%) and iMSCs#13(~69%) cell lines when incubated with 7% 
DOTMA and 15% DOTMA nioplexes (Fig. 4C), without differences be-
tween both formulations. Notably, viability of cells transfected with 
Lipofectamine was always significantly lower (~25%) than that 
observed with 7% DOTMA or 15% DOTMA nioplexes at any mass ratio 
tested, in both cell lines (p < 0.05). 
In a next step, cell studies were repeated in the presence of the 
lysosomotropic agent sucrose to elucidate whether the transfection ef-
ficiency of nioplexes may be enhanced due to a favored endosomal 
escape [34]. Selected formulations (non-filtered wF 7% DOTMA and 
15% DOTMA niosomes; to simplify, hereafter referred to 7% and 15% 
Fig. 2. Particle size, zeta potential and DNase protection ability of A) 0% DOTMA (P60/DNA mass ratios of 2.5/1, 5/1, 10/1, 15/1 and 20/1) B) 7% DOTMA 
(DOTMA/DNA mass ratios of 2.5/1, 5/1, 10/1, 15/1 and 20/1, equivalent to N/P ratios of 1, 2, 5, 7 and 10). and C) 15% DOTMA (DOTMA/DNA mass ratios of 2.5/1, 
5/1, 10/1, 15/1 and 20/1, equivalent to N/P ratios of 1,2, 5, 7 and 10) nioplexes prepared in water. Effect of filtration through PES-membrane (F) and cationic lipid 
or P60/DNA mass ratio on particle size (bars) and zeta potential (lines) (upper panels), and SDS-induced release and DNA protection at different niosome formu-
lations visualized by agarose electrophoresis (lower panels).OC: open circular; SC: supercoiled; 0: naked placZ. * depicts p < 0.05 and **p < 0.01 when compared 
particle size or zeta potential values obtained with nioplexes formed at the same cationic lipid/DNA mass ratio from filtered or non-filtered formulations. 
Fig. 3. DNA complexation efficiency of filtered (F; continuous line) and non- 
filtered (wF; dot line) dispersions of 0% DOTMA- (blue) (P60/DNA mass ra-
tios of 2.5/1, 5/1, 10/1, 15/1 and 20/1), 7% DOTMA- (black) (DOTMA/DNA 
mass ratios of 2.5/1, 5/1, 10/1, 15/1 and 20/1, equivalent to N/P ratios of 1, 2, 
5, 7 and 10) and 15% DOTMA (red) (DOTMA/DNA mass ratios of 2.5/1, 5/1, 
10/1, 15/1 and 20/1, equivalent to N/P ratios of 1, 2, 5, 7 and 10) based 
niosomes formulations. *Depicts p < 0.05, **p < 0.01 and ***p < 0.001 when 
comparing fluorescence intensity obtained with nioplexes formed at the same 
cationic lipid/DNA mass ratio from filtered or non-filtered formulations. (For 
interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article). 
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DOTMA), were formed at cationic lipid/DNA mass ratios of 5/1 and 10/ 
1, and tested under the same conditions and in the same lines described 
before, but adding sucrose 40 mM to the culture medium. Results 
showed an increase of β-galactosidase activity up to 2.6-fold with 7% 
DOTMA nioplexes at 5/1 ratio in iMSCs#6 cell line (p < 0.05), and up to 
3.8-fold with 15% DOTMA nioplexes at the same DOTMA/DNA ratio in 
iMSCs#13 cell line (p < 0.05) (Fig. 5). To further investigate the cellular 
uptake of nioplexes, Cy3-labeled placZ was used for transfection. A 
higher internalization of Cy3-labeled placZ was observed in presence of 
sucrose, as evidenced by the greater intensity of Cy3 fluorescence 
around the nucleus (Fig. S3 in Supporting Information). 
Transfection of iMSCs with nioplexes in the presence of sucrose did 
not show cytotoxic effects in any of the iMSCs cell lines. Interestingly, a 
significant increase in cell viability was noted in presence of sucrose 
upon transfection with nioplexes formed at DOTMA/DNA of 10/1 (7% 
DOTMA) and 5/1 (15% DOTMA) in the iMSCs#6 cell line (p < 0.05). 
Once again, treatment with Lipofectamine resulted in a significant 
decrease of cell survival (p < 0.05). 
3.4. Performance of stored niosomes to form nioplexes 
Physicochemical and transfection features of nioplexes formed from 
7% DOTMA and 15% DOTMA niosomes dispersions that had been stored 
for 30 days was investigated. The non-filtered (wF) niosomes dispersions 
were kept at room temperature and protected from light in order to 
check whether they could maintain their capability to form nioplexes 
after storage. Despite 7% DOTMA and 15% DOTMA niosomes did not 
significantly changed the size during storage (as reported in Fig. 1), 
nioplexes formed from stored niosomes dispersions were larger than 
those formed with fresh niosomes for all DOTMA/DNA ratios tested 
(Table 2) (p < 0.001). PDI values did not change. Also zeta potential 
values remained stable at 30 days except for those nioplexes formed at 
cationic lipid/DNA of 10/1, which showed a slight increase (p < 0.05). 
However, niosome capacity to protect DNA against DNase digestion was 
reduced, as noted by the absence of bands at DOTMA/DNA lower ratios 
(Fig. 6). A reduction on DNA complexation efficiency was also evidenced 
for niosomes stored for 30 days, always revealing higher percents of free 
DNA when compared with niosomes formulated at day 1 (p < 0.05) 
(Table 3). The changes in DNA binding suggest that niosome confor-
mation could have evolved along time. 
The transfection efficiencies were also reevaluated for nioplexes 
prepared using niosomes dispersions kept for 30 days at RT. The 
transfection efficiencies of iMSCs (iMSCs#6 cell line in upper panels, 
and iMSCs#13 cell lines in lower panels) attained with niosomes stored 
for 1 day or 30 days, either in presence or absence of sucrose in the 
culture medium, are compared in Fig. 7. No differences in β-galactosi-
dase activities were observed upon transfection when using fresh or 
long-term stored niosomes to form nioplexes with a DOTMA/DNA ratio 
of 10/1 in the iMSCs#6 cell line (either in presence or in absence of 
sucrose) (Fig. 7 upper panels). In contrast, a significant decrease in 
transfection efficiency was noted when using nioplexes prepared with 
the lowest DOTMA/DNA ratio tested (5/1), either in absence or presence 
of the lysosomotropic agent (p < 0.05). Conversely, when testing in 
iMSCs#13 cell line, nioplexes prepared with long-term stored niosomes 
showed a marked reduction in transfection values at DOTMA/DNA mass 
ratio of 10/1, either in absence (p < 0.05) or presence of sucrose (p <
0.05). 
3.5. Performance of nioplexes from niosomes sterilized in sucrose medium 
Since most biomedical applications of niosomes would require sterile 
formulations and steam heat sterilization is the approach of first choice, 
processing of niosomes in autoclave was investigated. To avoid the 
widely reported physical and chemical instability problems of vesicle- 
Fig. 4. In vitro studies performed in iMSCs#6 (upper panels) and iMSCs#13 (lower panels) cell lines. A) β-galactosidase activity preliminary screening of filtered (F, 
striped bars; values close to 0) and non-filtered (wF, full bars) 7% DOTMA and 15% DOTMA nioplexes (DOTMA/DNA mass ratios of 5/1, 10/1, 15/1 and 20/1, 
equivalent to N/P ratios of 2, 5, 7 and 10). B) β-galactosidase activity of non-filtered (wF) 7% DOTMA (black bars), 15% DOTMA (red bars) nioplexes (DOTMA/DNA 
mass ratios of 5/1, 10/1 and 15/1, equivalent to N/P ratios of 2, 5 and 7) or Lipofectamine (LPF; white bars). Lines represent cell numbers (7% DOTMA nioplexes: 
black line; 15% DOTMA nioplexes: red line; LPF: intersection of both lines). C) Cell viability in the presence of 7% DOTMA or 15% DOTMA nioplexes (DOTMA/DNA 
mass ratios of 5/1, 10/1 and 15/1, equivalent to N/P ratios of 2, 5 and 7) and LPF. ** depicts p < 0.01 upon comparison of the denoted groups (A) and * depicts p <
0.05 or ***p < 0.001 when compared the different nioplexes with LPF group (B and C). (For interpretation of the references to colour in this figure legend, the reader 
is referred to the web version of this article). 
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based drug carriers, sucrose was added to the niosomes with the two- 
fold aim of preserving niosome stability during sterilization [28] and 
acting as lysosomotropic agent. Niosomes were prepared by hydration of 
the components in 300 mM sucrose aqueous solution (isotonic) and then 
steam heat sterilized at 121 ◦C for 20 min. The niosomes were stored at 
room temperature for at least 24 h before subsequent evaluation of 
physical properties and transfection capability. The size of sterilized 7% 
and 15% DOTMA niosomes was 92.7 and 100.6 nm, with PDI of 0.594 
and 0.309, respectively. The Z-potential values were +31.8 (±7.6) and 
+40.7 (±7.5) mV, respectively. Size and PDI values were in the range of 
those recorded for non-filtered niosomes when stabilized during storage 
and to those of filtered niosomes. Only for sterilized 15% DOTMA nio-
somes the Z-potential was slightly lower (p < 0.05). A representative 
TEM image of 7 and 15% DOTMA niosomes after steam heat sterilization 
Fig. 5. In vitro studies performed in iMSCs#6 (upper panels) and iMSCs#13 (lower panels) cell lines in the presence of sucrose (added to the cell culture medium) A) 
β-galactosidase activity of 7% DOTMA and 15% DOTMA nioplexes (DOTMA/DNA mass ratios of 5/1 and 10/1, equivalent to N/P ratios of 2 and 5) obtained in 
absence (grey bars) and in the presence (black bars) of sucrose. LPF (white bars) was used as positive control of transfection. Lines represent cell number in absence 
(green lines) or presence (blue lines) of sucrose, and after being transfected with LPF (confluence of both lines) B) Cell viability upon contact with LPF (white bars) or 
with nioplexes (DOTMA/DNA mass ratios of 5/1 and 10/1, equivalent to N/P ratios of 2 and 5) formulated with 7% DOTMA or 15% DOTMA, in absence (grey bars) 
or presence (black bars) of sucrose. * depicts p < 0.05 and **p < 0.01 upon comparison of the denoted groups. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article). 
Table 2 
Particle size, PDI and zeta potential of nioplexes prepared with 7% and 15% DOTMA niosomes (DOTMA/DNA mass ratios of 2.5/1, 5/1, 10/1, 15/1 and 20/1, 
equivalent to N/P ratios of 1, 2, 5, 7 and 10). Niosomes were stored for 1 day or 30 days at room temperature and protected from light before nioplexes preparation. 
Mean values ± standard deviation (n = 3).   
DOTMA/DNA ratio Day 1 Day 30 
Size (nm) PDI Z-potential   
(mV) 
Size (nm) PDI Z-potential   
(mV) 
7% DOTMA 2.5/1 272 ± 23 0.28 ± 0.02 − 10.0 ± 1.1 530 ± 11 0.28 ± 0.01 − 5.6 ± 0.6 
5/1 210 ± 12 0.35 ± 0.15 − 0.8 ± 1.1 464 ± 38 0.33 ± 0.04 1.3 ± 1.8 
10/1 145 ± 5 0.23 ± 0.04 2.9 ± 0.0 329 ± 9 0.27 ± 0.03 4.4 ± 0.0 
15/1 134 ± 7 0.26 ± 0.03 26.8 ± 5.2 345 ± 15 0.29 ± 0.04 6.5 ± 3.0 
20/1 131 ± 13 0.26 ± 0.06 25.9 ± 2.1 200 ± 9 0.29 ± 0.01 12.4 ± 0.6 
15% DOTMA 2.5/1 275 ± 17 0.28 ± 0.03 − 4.7 ± 2.1 544 ± 35 0.30 ± 0.06 0.9 ± 0.0 
5/1 187 ± 11 0.30 ± 0.02 − 1.5 ± 0.0 394 ± 10 0.29 ± 0.00 2.0 ± 1.6 
10/1 154 ± 1 0.27 ± 0.01 2.8 ± 0.0 330 ± 9 0.27 ± 0.03 7.3 ± 0.6 
15/1 150 ± 1 0.27 ± 0.01 15.2 ± 0.5 321 ± 6 0.29 ± 0.00 12.5 ± 5.5 
20/1 155 ± 1 0.26 ± 0.01 28.8 ± 0.9 223 ± 3 0.30 ± 0.00 27.4 ± 8.3  
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in sucrose medium is shown in Fig. S4 (Supporting Information). 
When studying β-galactosidase activity of sh niosomes no differences 
on RLU values were observed between 7% DOTMA and 15% DOTMA 
formulations, in none of the two cell lines studied (p > 0.05) (Fig. 8). 
Interestingly, incorporation of sucrose to sh niosomes formulations 
resulted in a higher increment of β-galactosidase values (p < 0.05; up to 
31.3-fold compared with wF niosomes) than those achieved by direct 
addition of sucrose into the culture medium (Fig. 5). Formulation of the 
positive control LPF in sucrose also resulted in an enhancement of 
transfection values compared with niosomes formulations (p < 0.001). 
Likewise in good concordance with previous results (Fig. 5), viability of 
cells transfected with Lipofectamine was always significantly lower than 
that reached with 7% DOTMA and 15% DOTMA nioplexes (p < 0.001). 
4. Discussion 
Transfection efficiency of nonviral vectors has been shown to 
strongly depend on multiple parameters including particle size, zeta 
potential and capacity to protect DNA from the cellular environment 
Fig. 6. SDS-induced release and DNA protection ability of different niosomes formulations visualized by agarose electrophoresis. The nioplexes (DOTMA/DNA mass 
ratios of 2.5/1, 5/1, 10/1, 15/1 and 20/1, equivalent to N/P ratios of 1, 2, 5, 7 and 10) were prepared with niosomes stored for 1 day (left) or for 30 days (right) at 
room temperature and protected from light. 0: naked placZ; OC: open circular; SC: supercoiled. 
Table 3 
DNA complexation efficiency of 7% DOTMA and 15% DOTMA nioplexes 
(DOTMA/DNA mass ratios of 2.5/1, 5/1, 10/1, 15/1 and 20/1, equivalent to N/ 
P ratios of 1, 2, 5, 7 and 10) when prepared with niosomes stored for 1 day or for 
30 days at room temperature and protected from light. Mean values ± standard 
deviation (n = 3).   
DOTMA/DNA 
ratio 







2.5/1 100.0 ± 0.8 88.3 ± 2.4 
5/1 59.4 ± 1.9 68.9 ± 1.4 
10/1 49.4 ± 4.2 49.0 ± 7.9 
15/1 44.0 ± 3.6 48.1 ± 1.6 
20/1 49.5 ± 5.1 41.9 ± 1.9 
15% 
DOTMA 
2.5/1 51.4 ± 5.9 85.6 ± 2.4 
5/1 43.5 ± 1.0 81.7 ± 1.4 
10/1 41.5 ± 3.4 69.2 ± 7.9 
15/1 37.3 ± 2.4 51.2 ± 1.6 
20/1 38.3 ± 0.4 47.3 ± 1.9  
Fig. 7. In vitro transfection studies per-
formed in iMSCs#6 (upper panels) and 
iMSCs#13 (lower panels) cell lines. 
β-galactosidase activities of nioplexes 
(DOTMA/DNA mass ratios of 5/1 and 
10/1, equivalent to N/P ratios of 2 and 
5) formed from 7% DOTMA and 15% 
DOTMA based niosomes formulations 
stored for 1 day (white bars) or 30 days 
(black bars), in absence (left panels) or 
in presence (right panels) of sucrose. * 
depicts p < 0.05 when compared 
β-galactosidase activity between day 1 
and day 30.   
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[10,15]. Various niosomes formulations based on the combination of the 
cationic lipid DOTMA with different non-ionic surfactants and helper 
lipids have demonstrated successful transfection of retina pigment 
epithelial cells [24,35] or primary neuronal cells [20]. However, up to 
date very little is known about the use of niosomes as delivery systems to 
genetically modify MSCs, which is a target cell population in different 
regenerative medicine approaches [3]. Based on this, the main goal of 
the present study was to design effective niosomes-based DNA delivery 
platforms for targeting immortalized human MSCs cell lines obtained 
from aged donors. To this end, a set of niosomes dispersions based on 
polysorbate 60 as non-ionic surfactant, cholesterol as helper lipid, and 
DOTMA as cationic lipid were prepared. To analyze the effect of cationic 
lipid content on physicochemical and biological properties of nioplexes, 
the niosomes dispersions were prepared tuning the content in DOTMA 
(0, 7 and 15 mol%). Likewise, the effect of niosomes filtration on the 
physicochemical properties and the gene transfer efficiency of the 
resulting nioplexes was evaluated. 
The data from the present study first revealed an influence of 
DOTMA concentration on physicochemical properties and complexation 
ability. Niosomes formulated without DOTMA exhibited the highest 
sizes and the lowest zeta potential values, failing to condense and pro-
tect placZ against DNAase degradation. These observations evidenced 
the role of the cationic lipid in complexing and condensing the DNA 
molecule [15]. The ability of niosomes formulated without DOTMA to 
protect placZ against DNase degradation at the highest P60/DNA ratio 
tested (20/1) may be due to hydrophobic interactions between the non- 
ionic surfactant and the DNA molecule [13] playing a protective role by 
the creation of a steric barrier [36] that reduces the interaction with 
nucleases [37]. 
In good agreement with previous works, 7% and 15% DOTMA 
nioplexes showed discrete oscillations in particle size upon the addition 
of placZ at the different cationic lipid/DNA (2.5/1, 5/1, 10/1, 15/1 and 
20/1) ratios or N/P ratios (1, 2, 5, 7 and 10) studied [23]. These ob-
servations may be due to the balance between larger space demanded by 
the cationic lipid and the higher DNA condensation when increasing 
mass ratio [38] as confirmed in DNA complexation assays. Therefore, 
both 7% and 15% DOTMA niosomes showed ability to complex placZ, 
which was more evident for nioplexes formed from niosomes dispersions 
containing the highest concentration of cationic lipid (15%). It is known 
that positive zeta potential values promote electrostatic interactions 
with negatively charged DNA molecules [39]. Niosomes formulated 
with either 7% or 15% DOTMA concentration showed zeta potential 
values around +40 mV, being suitable for transfection assays according 
to previous works [23,25]. Likewise, surface charge increased with the 
raise of cationic lipid/DNA ratio [40]. 
Since filtration is an extensively used procedure for nanocarrier 
purification, the effect of niosomes dispersions filtering on the physi-
cochemical properties of resulting nioplexes was investigated. A modi-
fication of niosomes properties as nonviral gene delivery systems was 
noticed upon initial filtration of niosomes dispersions, resulting in a 
reduction of both the size and PDI of resulting nioplexes. Moreover, 
while filtration of 7% DOTMA dispersions did not show evident changes 
in zeta potential values at lower DOTMA/DNA ratios, a decrease in the 
electro-positivity was evidenced at the highest DOTMA/DNA ratios (15/ 
1 and 20/1). The effect of filtration on surface charge was not so evident 
for nioplexes formulated with higher percent of cationic lipid (15%), 
showing still higher complexation ability than those nioplexes formu-
lated with non-filtered niosomes dispersions. The discrepancies 
observed here in physicochemical features of niosomes may help to 
support previous observations indicating that membrane filtration is not 
Fig. 8. In vitro transfection studies performed in iMSCs#6 and iMSCs#13 cell lines. β-Galactosidase activities of nioplexes (DOTMA/DNA mass ratios of 5/1, 10/1 
and 15/1, equivalent to N/P ratios of 2, 5 and 7) formed from 7% DOTMA and 15% DOTMA based niosomes formulations prepared in sucrose 300 mM and heat 
sterilized (sh). Lipoplexes formulated with the positive control Lipofectamine (LPF) were prepared under the same conditions as nioplexes. *** depicts p < 0.001 
when compared the different cationic lipid/DNA mass ratios of both nioplexes with LPF group. 
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a suitable procedure for niosomes purification [41]. 
Agarose gel retardation assays revealed that both 7% and 15% 
DOTMA niosomes formulations were able to condense, release and 
protect DNA from enzymatic digestion, as confirmed by the presence of 
SC bands [22]. Interestingly, formulations with lower cationic lipid 
content (7%) enhanced protection of complexed DNA at lower DOTMA/ 
DNA ratios in non-filtered dispersions. 
In order to test the performance of developed formulations for gene 
delivery purposes, transfection assays were carried out in two different 
immortalized MSCs cell lines obtained from bone marrow samples of 
aged donors. These cell lines have previously shown to prevent senes-
cence and proliferation concerns associated to primary cultures while 
maintaining their multipotency; therefore, iMSCs are considered as 
potential means for regenerative medicine research [26]. Strikingly, 
despite their lower size and higher placZ complexation ability, nioplexes 
formed from filtered niosomes dispersions (7 and 15%) failed to transfer 
placZ in both iMSCs lines tested. Conversely, nioplexes based on non- 
filtered 7 and 15% DOTMA formulations led to an effective trans-
fection of both iMSCs cell lines with values similar to that achieved with 
the commercial reagent Lipofectamine. These observations are in 
agreement with previous studies noticing a higher transfection effi-
ciency with larger liposomes when compared with smaller and mono-
disperse ones obtained by filtration [42]. Hence, and similarly to that 
observed with lipoplexes, larger nioplexes may facilitate cell surface 
contact by sedimentation resulting in a higher gene transfer [42,43]. 
Moreover, these results highlight the need of an adequate balance be-
tween complexes stability and their ability to deliver the DNA molecules 
inside the cell to achieve an effective transfection [30]. Of note, while 
7% DOTMA nioplexes may be more efficient when used at the lowest 
DOTMA/DNA ratio (5/1), 15% DOTMA nioplexes achieved the highest 
efficiency at an intermediate ratio (10/1). Along these lines, the elec-
troneutral to slightly positive zeta potential values detected for these 
nioplexes were sufficient for condensing and protecting the DNA 
molecule, which in turn favored its uptake into the cell and prevented 
cell membrane disruption [44]. Finally, viability of cells transfected 
with 7% or 15% DOTMA nioplexes was always higher than that 
observed for the gold standard Lipofectamine, at any mass ratio tested in 
both cell lines. These results are in agreement with previous reports 
showing a reduction of MSCs viability in the presence of this commercial 
reagent [45]. 
It is known that endosomal escape constitutes one of the least un-
derstood steps precluding the effectiveness of nonviral gene delivery 
[46]. Thereupon, improving endosomal escape might significantly 
improve transfection efficiency. Based on this, cell studies were repeated 
in the presence of the lysosomotropic agent sucrose, due to its ability to 
cause cytoplasmatic vesicular swelling within endosomes and lysosomes 
[34]. Results showed an increase of β-galactosidase activity in both cell 
lines at all DOTMA/DNA ratio tested, mostly at the lowest DOTMA/DNA 
ratio tested. Likewise, in good agreement with previous studies per-
formed in fibroblasts [34], transfection of iMSCs with nioplexes in the 
presence of sucrose at 40 mM concentration did not show cytotoxic ef-
fects in any of the iMSCs cell lines. Thus, sucrose could be used as an 
excipient in the formulation of niosomes based gene delivery systems. 
Consequently, performance of niosomes formulated in sucrose-added 
medium was explored as a proof of concept in the last part of the 
work. Preparation of niosomes by hydration of the components in 
isotonic sucrose aqueous solution and subsequent sterilization by steam 
heat resulted in an enhancement of transfection efficiency compared 
with niosomes prepared in Opti-MEM medium (as explained below). 
Storage of niosomes at 25 ◦C during several weeks may affect main 
physicochemical parameters influencing gene delivery process [35]. In 
agreement with previous works [35], nioplexes formed from long-term 
stored niosomes showed an increase in size. The surface charge resul-
ted only modified in those nioplexes formed at cationic lipid/DNA ratio 
of 10/1. These results contrast with previous observations using nio-
somes based on DOTMA, squalene and polysorbate 20 in which a more 
drastic reduction of zeta potential values was observed [35]. In this 
sense, the different composition of helper lipid and non-ionic surfactant 
from these niosomes as well as the size of plasmid used, may explain 
these discrepancies. In consonance with previous reports, niosomes ca-
pacity to protect DNA against DNase digestion was reduced at lower 
DOTMA/DNA ratios [35]. Similarly, a reduction of DNA complexation 
efficiency was also evidenced upon storage of niosomes for 30 days, 
revealing always higher percentages of free DNA when compared with 
niosomes formulated at day 1. When studying transfection efficiency, no 
differences in β-galactosidase activity were observed with nioplexes 
formed from long-term stored niosomes from DOTMA/DNA ratio of 10/ 
1 in one of the iMSCs cell lines tested (iMSCs#6). Conversely, in the 
other iMSCs cell line (iMSCs#13) long-term stored niosomes showed a 
marked reduction of transfection values at DOTMA/DNA mass ratio of 
10/1 from nioplexes. It is known that niosome composition has a direct 
influence on its transfection capacity, but other factors such as changes 
in niosome conformation (oriented components, aggregation) as well as 
the cell type and the specific cell internalization pathway also determine 
the transfection efficiency [47]. Hence, it is important to highlight that 
iMSCs cell lines used in the present study were obtained from bone 
marrow samples of patients undergoing hip osteoarthritis or fracture, so 
these differences may be attributed to the variability inextricably linked 
to biological samples [26]. In this sense, future studies involving a 
higher number of iMSCs cell lines may help to clarify these observations. 
Finally, and regarding niosomes stability and scaling-up toward 
clinical use, a sterilization protocol using sucrose as stabilizing agent 
was implemented. The use of sucrose at concentration close to that 
required for being isotonic to blood serum (300 mM) has been demon-
strated suitable to prevent aggregation and membrane permeabilization 
of liposomes during autoclaving [28]. No report was found for niosomes. 
Niosomes formulated in 300 mM sucrose medium withstood the steam 
heat sterilization process and showed adequate physical features. Since 
the nioplexes were tested under 1/10 dilution, the formulation could 
still provide 30 mM sucrose to the medium and then took benefit from its 
lysosomotropic features. Indeed, to the best of our knowledge this is the 
first time that the transfection capability of steam heat-sterilized nio-
somes was demonstrated. 
5. Conclusions 
Niosomes formulated with DOTMA as cationic lipid, cholesterol as 
helper lipid and polysorbate 60 as non-ionic surfactant are revealed as 
suitable nonviral gene delivery platforms for the effective gene transfer 
of immortalized MSCs. Specifically, nioplexes formed from non-filtered 
15% DOTMA niosomes dispersions led to an effective DNA protection 
and complexation, attaining similar transfection values to those ach-
ieved with the gold standard reagent Lipofectamine with a marked lower 
cytotoxicity in the two iMSCs cell lines tested. Addition of sucrose into 
the culture medium during transfection process or to the formulati+on 
itself considerably improved the gene transfer performance from these 
nioplexes. Both filtration during niosomes formulation and storage of 
niosomes formulations for 30 days at RT modified physicochemical 
properties from resulting nioplexes leading to a decrease of their gene 
transfer efficiency. Further experiments will focus in further evaluation 
of the filtration and sterilization processes that may help niosomes to 
maintain the transfection capability during long term storage. 
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